Inovio Pharmaceuticals (INO)
NASDAQ:INO
Want to see INO full AI Analyst Report?
INO Stock Chart & Stats
$1.19
-$0.22(-9.65%)
At close: 4:00 PM EST
$1.19
-$0.22(-9.65%)
Day’s Range― - ―
52-Week Range$1.03 - $2.98
Previous CloseN/A
Volume1.36M
Average Volume (3M)3.22M
Market Cap
$91.73M
Enterprise Value$41.91M
Total Cash (Recent Filing)$37.68M
Total Debt (Recent Filing)$8.70M
Price to Earnings (P/E)―
Beta1.57
Next Earnings
Aug 12, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.71
Shares Outstanding82,273,240
10 Day Avg. Volume1,397,164
30 Day Avg. Volume3,223,112
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)33.86
Price to Sales (P/S)12485.24
P/FCF Ratio-9.18
Enterprise Value/Market Cap0.46
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-18.70
Enterprise Value/Ebitda-0.51
Forecast
1Y Price Target
$4.25Price Target Upside257.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.89
Revenue Forecast (FY)$8.90M
Bulls Say, Bears Say
Bulls Say
Regulatory Progress On INO-3107Acceptance of the BLA and a set PDUFA date materially advances the program from pre-approval to a defined regulatory timeline. Mid-cycle review with no new issues narrows regulatory uncertainty, enabling the company to focus resources on approval, launch planning and partner commitments over the coming months.
Strong Phase I/II Efficacy And Product DifferentiationDurable, clinically meaningful reductions in surgeries and a favorable safety profile versus comparator support a differentiated label and easier patient adoption. The lack of surgery requirement and simpler logistics underpin sustainable commercial positioning and lower barriers to physician uptake over time.
Platform Partnerships And Pipeline DiversificationStrategic collaborations and expansion of the DPROT platform create multiple development pathways and potential non-dilutive support. Partnerships with academic and industry groups diversify technical risk, accelerate indication expansion and increase the probability of mid-term value realization beyond a single program.
Bears Say
Very Weak Financial ProfileEffectively zero trailing revenue, persistent operating and free cash flow deficits, and recent leverage deterioration indicate constrained internal funding capacity. This structural financial weakness limits flexibility to execute programs without dilution or costly external financing, raising solvency and continuity risk.
Limited Cash Runway & High Near-term BurnA substantial quarterly cash burn and a runway into only Q1 2027 (excluding future raises) mean the company will likely need more capital to complete regulatory and commercialization steps. Future financing needs can delay programs, impose dilution and complicate long-term planning across development programs.
Regulatory Uncertainty On Accelerated-approval EligibilityA potential eligibility issue for accelerated approval and unresolved confirmatory-trial feedback are structural risks that could alter approval pathway, require additional data or protocol changes, extend timelines, and increase costs—any of which would materially affect commercialization timing and resource needs.
Inovio Pharmaceuticals News
INO FAQ
What was Inovio Pharmaceuticals’s price range in the past 12 months?
Inovio Pharmaceuticals lowest stock price was $1.03 and its highest was $2.98 in the past 12 months.
What is Inovio Pharmaceuticals’s market cap?
Inovio Pharmaceuticals’s market cap is $91.73M.
When is Inovio Pharmaceuticals’s upcoming earnings report date?
Inovio Pharmaceuticals’s upcoming earnings report date is Aug 12, 2026 which is in 53 days.
How were Inovio Pharmaceuticals’s earnings last quarter?
Inovio Pharmaceuticals released its earnings results on May 13, 2026. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.35 by $0.07.
Is Inovio Pharmaceuticals overvalued?
According to Wall Street analysts Inovio Pharmaceuticals’s price is currently Undervalued.
Does Inovio Pharmaceuticals pay dividends?
Inovio Pharmaceuticals pays a Monthly dividend of $0.069 which represents an annual dividend yield of N/A. See more information on Inovio Pharmaceuticals dividends here
What is Inovio Pharmaceuticals’s EPS estimate?
Inovio Pharmaceuticals’s EPS estimate is -0.24.
How many shares outstanding does Inovio Pharmaceuticals have?
Inovio Pharmaceuticals has 82,273,240 shares outstanding.
What happened to Inovio Pharmaceuticals’s price movement after its last earnings report?
Inovio Pharmaceuticals reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.35. Following the earnings report the stock price went up 1.493%.
Which hedge fund is a major shareholder of Inovio Pharmaceuticals?
Currently, no hedge funds are holding shares in INO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inovio Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.25 (257.14% Upside)
$4.25 (257.14% Upside)
Blogger Sentiment
Bullish
INO Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 126.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 4.1%
Last 30 Days ▲ 4.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.82%
12-Months-Change
Fundamentals
Return on Equity
-666.47%
Trailing 12-Months
Asset Growth
-42.96%
Trailing 12-Months
Company Description
Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.
INO Company Deck
INO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial progress on multiple fronts—regulatory milestones (BLA accepted, mid-cycle review with no new issues, PDUFA date set), strong Phase I/II efficacy/safety signals, commercial preparation and advancing partnerships—tempered by material near-term financial constraints (cash declined ~36%, an $18M estimated Q2 burn and runway into only Q1 2027), outstanding regulatory questions about accelerated approval eligibility and an active competitive landscape. Overall the tone was optimistic about the program and platform advancement but realistic about financing and regulatory uncertainties.View all INO earnings summariesINO Stock 12 Month Forecast
Average Price Target
$4.25
▲(257.14% Upside)
Technical Analysis
Ownership Overview
0.47% Insiders
16.50% Mutual Funds
8.78% Other Institutional Investors
69.99% Public Companies and
Individual Investors